NOTICE - SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations of the Following Companies: PropTech Acquisition Corporation (NasdaqCM - PTAC), ARYA Sciences Acquisition Corp II (NasdaqGS - ARYBU), Spring Bank Pharmaceuticals, Inc. (NasdaqGS - SBPH)
BALA CYNWYD, PA / ACCESSWIRE / August 3, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.
PropTech Acquisition Corporation (NASDAQCM:PTAC)
Under the terms of the agreement, PropTech shareholders will retain ownership of only 22% of the combined company. The investigation concerns whether the PropTech Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.
Additional information can be found at http://www.brodskysmith.com/cases/proptech-acquisition-corporation-nasdaqcm-ptac/, or call 877-534-2590. No cost or obligation to you.
ARYA Sciences Acquisition Corp II (NASDAQGS:ARYBU)
Under the terms of the agreement, ARYA Sciences shareholders will retain ownership of only 12% of the combined company. The investigation concerns whether the ARYA Sciences Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.
Additional information can be found at http://www.brodskysmith.com/cases/arya-sciences-acquisition-corp-ii-nasdaqgs-arybu/, or call 877-534-2590. No cost or obligation to you.
Spring Bank Pharmaceuticals, Inc. (NASDAQGS:BPH)
Under the terms of the share exchange agreement, Spring Bank shareholders will be significantly diluted, holding only approximately 38.8% of the combined company, and receiving two Contingent Value Rights ("CVR") with respect to certain Spring Bank programs. The investigation concerns whether the Spring Bank Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.
Additional information can be found at http://www.brodskysmith.com/cases/spring-bank-pharmaceuticals-inc-nasdaqgs-sbph/, or call 877-534-2590. No cost or obligation to you.
Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
SOURCE: Brodsky & Smith, LLC
View source version on accesswire.com:
https://www.accesswire.com/600103/NOTICE--SHAREHOLDER-INVESTIGATION-UPDATE-Brodsky-Smith-LLC-Reminds-Investors-of-Investigations-of-the-Following-Companies-PropTech-Acquisition-Corporation-NasdaqCM--PTAC-ARYA-Sciences-Acquisition-Corp-II-NasdaqGS--ARYBU-Spring-Bank-Pharmaceuticals
